[Incidence and pathological features of incidental prostate cancer and clinical significance thereof]. 2007

Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
Department of Urology, First Hospital of Peking University, Institute of Urology, Peking University, Beijing 100034, China.

OBJECTIVE To investigate the morbidity and pathological features of incidental prostate cancer and their clinical significance. METHODS 1483 prostate specimens obtained during operation, including transurethral resection of prostate (TURP) and total resection of the prostate, for the diagnoses of benign prostatic hypertrophy (BPH) or bladder cancer between January 1999 and August 2005 underwent pathological examination and 34beta12 and p63 immunohistochemical staining so as to detect incidental prostate cancer. The volume of incidental prostate cancer was calculated by the image analysis system. The clinical data were analyzed retrospectively. Comparison between the clinical and pathological feature of incidental prostate cancer was made. RESULTS 53 cases of incidental prostate cancer, with the Gleason scores from 2 (1+1) to 9 (4+5) and the volumes from 0.18 to 1440.00 mm(3) were detected. The morbidity of incidental prostate cancer was 3.6%. The volume of 47 cases (88.7%) were less than 0.5 cm(3) as the threshold of insignificant cancer, and the volumes of 6 cases (11.3%) were more than 0.5 cm(3). All incidental prostate cancers of clinical significance were detected in the TURP samples. Among the incidental prostate cancers found in the TURP samples 20% were clinically significant cancers. The clinically significant incidental cancers were located in the central or transitional zone with the Gleason scores of 3 + 4 (2 cases), 4 + 2 (1 case), or 4 + 5 (3 cases). These clinically significant cancers were of diffuse distribution, and their preoperative clinical features were negative in palpation/image examination, elevation of serum PSA, and negative in puncture examination. CONCLUSIONS Nowadays, the morbidity of incidental prostate cancer is lower than that of 1980s'. Among the incidental cancers 11.3% were of clinical significance. That the preoperative clinical examination cannot find these clinical significant cancers is partially caused by the pathological features of these tumors.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D007633 Keratins A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION. Cytokeratin,Keratin Associated Protein,Keratin,Keratin-Associated Proteins,alpha-Keratin,Associated Protein, Keratin,Keratin Associated Proteins,Protein, Keratin Associated,alpha Keratin
D008297 Male Males
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D002681 China A country spanning from central Asia to the Pacific Ocean. Inner Mongolia,Manchuria,People's Republic of China,Sinkiang,Mainland China
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription

Related Publications

Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
June 1996, The Journal of urology,
Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
August 2020, The Journal of urology,
Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
January 2004, Revista da Associacao Medica Brasileira (1992),
Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
June 2021, The Journal of urology,
Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
June 2021, The Journal of urology,
Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
January 1965, CA: a cancer journal for clinicians,
Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
April 2024, Virchows Archiv : an international journal of pathology,
Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
March 1995, The Journal of urology,
Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
July 1991, Hinyokika kiyo. Acta urologica Japonica,
Xin-Yu Yang, and Tong-Li Xia, and Qun He, and Wen Li, and Jing-Hua Wang, and Jin-Wei Su, and Jun Li, and Yan-Qun Na
January 2014, PloS one,
Copied contents to your clipboard!